litlas
Log inCreate account

Alan Sandler

Active 1995–2020

44
Papers
41,225
Citations
44
h-index
44
i10-index

Citations

Citations per year for Alan Sandler1997: 1 citations1999: 3 citations2000: 7 citations2001: 7 citations2002: 33 citations2003: 46 citations2004: 118 citations2005: 215 citations2006: 210 citations2007: 262 citations2008: 251 citations2009: 319 citations2010: 281 citations2011: 246 citations2012: 211 citations2013: 196 citations2014: 156 citations2015: 148 citations2016: 200 citations2017: 336 citations2018: 436 citations2019: 1,688 citations2020: 2,065 citations2021: 1,999 citations2022: 1,441 citations2023: 979 citations2024: 1,312 citations2025: 539 citations2026: 6 citations1998: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,833 citing papers, 23.8% of this breakdownChina: 2,547 citing papers, 15.8% of this breakdownJapan: 968 citing papers, 6% of this breakdownItaly: 877 citing papers, 5.4% of this breakdownFrance: 754 citing papers, 4.7% of this breakdownUnited Kingdom: 754 citing papers, 4.7% of this breakdownGermany: 667 citing papers, 4.1% of this breakdownSpain: 603 citing papers, 3.7% of this breakdownCanada: 490 citing papers, 3% of this breakdownSouth Korea: 407 citing papers, 2.5% of this breakdownSwitzerland: 382 citing papers, 2.4% of this breakdownAustralia: 371 citing papers, 2.3% of this breakdown
0%23.8%Other 21.6%

Institutions

Fields

  • Medicine78.7%
  • Biochemistry, Genetics and Molecular Biology14.6%
  • Immunology and Microbiology3.4%
  • Engineering0.6%
  • Materials Science0.5%
  • Mathematics0.5%
  • Other1.7%

Topics

  • Cancer Immunotherapy and Biomarkers15.2%
  • Lung Cancer Treatments and Mutations11.9%
  • Lung Cancer Research Studies8.9%
  • Lung Cancer Diagnosis and Treatment4.9%
  • Immunotherapy and Immune Responses3%
  • Cancer Genomics and Diagnostics2.9%
  • Other53.2%

Coauthors

All papers

Open in search
  1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    Authors: Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu - New England Journal of Medicine 2018 cited by 3,507

  2. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Authors: Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck - New England Journal of Medicine 2018 cited by 3,753

  3. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

    Authors: Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara - The Lancet 2016 cited by 4,780

  4. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

    Authors: Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel - New England Journal of Medicine 2020 cited by 1,691

  5. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

    Authors: Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steven McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, Ahad A. Sadiq, Alan Sandler, Wei Lin, Tania Ochi Lohmann, Venice Archer, Lijia Wang, Marcin Kowanetz, Federico Cappuzzo - The Lancet Oncology 2019 cited by 1,681

  6. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

    Authors: Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazières, Keunchil Park, David C. Smith, Á. Artal, C. Lewanski, Fadi Braiteh, Daniel Waterkamp, Pei He, Wei Zou, Daniel S. Chen, Jing Yi, Alan Sandler, Achim Rittmeyer - The Lancet 2016 cited by 2,803

  7. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    Authors: David R. Gandara, Sarah Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine M. Malboeuf, Daniel S. Lieber, Doron Lipson, Jacob Silterra, Lukas C. Amler, Todd Riehl, Craig Cummings, Priti S. Hegde, Alan Sandler, Marcus Ballinger, David Fabrizio, Tony Mok, David S. Shames - Nature Medicine 2018 cited by 1,195

  8. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

    Authors: Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski - Journal of Thoracic Oncology 2020 cited by 607

  9. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

    Authors: Alan Sandler, Robert J. Gray, Michael C. Perry, Julie R. Brahmer, Joan H. Schiller, Afshin Dowlati, Rogério Lilenbaum, David H. Johnson - New England Journal of Medicine 2006 cited by 5,778

  10. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

    Authors: Joan H. Schiller, David Harrington, Chandra P. Belani, Corey J. Langer, Alan Sandler, James E. Krook, Junming Zhu, David H. Johnson - New England Journal of Medicine 2002 cited by 4,984

  11. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

    Authors: Solange Peters, Scott Gettinger, Melissa L. Johnson, Pasi A. Jänne, Marina Chiara Garassino, Daniel C. Christoph, Chee‐Keong Toh, Naiyer A. Rizvi, Jamie E. Chaft, Enric Carcereny, Jyoti D. Patel, Laura Q.M. Chow, Marianna Koczywas, Cheryl Ho, Martin Früh, Michel M. van den Heuvel, J. Rothenstein, Martin Reck, Luis Paz‐Ares, Frances A. Shepherd, Takayasu Kurata, Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, Alan Sandler, Enriqueta Felip - Journal of Clinical Oncology 2017 cited by 419

  12. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

    Authors: Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, Achim Rittmeyer, David R. Gandara, Santiago Ponce Aix, Ji‐Youn Han, Shirish M. Gadgeel, Toyoaki Hida, Diego Cortinovis, Manuel Cobo, Dariusz M. Kowalski, Filippo de Marinis, Mayank Gandhi, Bradford J. Danner, Christina Matheny, Marcin Kowanetz, Pei He, Federico Felizzi, Hina Patel, Alan Sandler, Marcus Ballinger, Fabrice Barlési - Journal of Thoracic Oncology 2018 cited by 261

  13. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

    Authors: Marcin Kowanetz, Wei Zou, Scott Gettinger, Hartmut Koeppen, Mark Kockx, Peter Schmid, Edward E. Kadel, Ignacio I. Wistuba, Jamie E. Chaft, Naiyer A. Rizvi, David R. Spigel, Alexander I. Spira, Fred R. Hirsch, Victor Cohen, Dustin Smith, Zach Boyd, Natasha Miley, Susan Flynn, Vincent Lévêque, David S. Shames, Marcus Ballinger, Simonetta Mocci, Geetha Shankar, Roel Funke, Garret M. Hampton, Alan Sandler, Lukas C. Amler, Ira Mellman, Daniel S. Chen, Priti S. Hegde - National Academy of Sciences, Proceedings of the National Academy of Sciences 2018 cited by 239

  14. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

    Authors: David R. Gandara, Joachim von Pawel, Julien Mazières, Richard Sullivan, Åslaug Helland, Ji‐Youn Han, Santiago Ponce Aix, Achim Rittmeyer, Fabrice Barlési, Toshio Kubo, Keunchil Park, Jerome H. Goldschmidt, Mayank Gandhi, Cindy Yun, Wei Yu, Christina Matheny, Pei He, Alan Sandler, Marcus Ballinger, Louis Fehrenbacher - Journal of Thoracic Oncology 2018 cited by 163

  15. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

    Authors: Shirish M. Gadgeel, Rimas V. Lukas, Jerome H. Goldschmidt, Paul Conkling, Keunchil Park, Diego Cortinovis, Filippo de Marinis, Achim Rittmeyer, Jyoti D. Patel, Joachim von Pawel, Carol O’Hear, Catherine Lai, Sylvia Hu, Marcus Ballinger, Alan Sandler, Mayank Gandhi, L. Fehrenbacher - Lung Cancer 2018 cited by 172

  16. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

    Authors: Mark G. Kris, Ronald B. Natale, Roy S. Herbst, T. J. Lynch, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, H. Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael Wolf, Steven D. Averbuch, Judith Ochs, Andrea Kay - JAMA 2003 cited by 2,538

  17. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

    Authors: Nasser H. Hanna, Paul A. Bunn, Corey J. Langer, Lawrence H. Einhorn, Troy H. Guthrie, Thaddeus Beck, Rafat Ansari, Peter Ellis, Michael Byrne, Mark E. Morrison, Subramanian Hariharan, Benjamin Wang, Alan Sandler - Journal of Clinical Oncology 2006 cited by 678

  18. Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial

    Authors: Ariel López-Chávez, Anish Thomas, Arun Rajan, Mark Raffeld, Betsy Morrow, Ronan J. Kelly, Corey Allan Carter, Udayan Guha, Keith Killian, Christopher Lau, Zied Abdullaev, Liqiang Xi, Svetlana Pack, Paul S. Meltzer, Christopher L. Corless, Alan Sandler, Carol Beadling, Andrea Warrick, David J. Liewehr, Seth M. Steinberg, Arlene Berman, Austin Doyle, Éva Szabó, Yisong Wang, Giuseppe Giaccone - Journal of Clinical Oncology 2015 cited by 235

  19. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

    Authors: David R. Spigel, Jamie E. Chaft, Scott Gettinger, Bo H. Chao, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Rodney J. Hicks, Larry Leon, Jill Fredrickson, Marcin Kowanetz, Alan Sandler, Roel Funke, Naiyer A. Rizvi - Journal of Thoracic Oncology 2018 cited by 172

  20. Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models

    Authors: Jeffrey M. Albert, Carolyn Cao, Kwang Woon Kim, Christopher D. Willey, Ling Geng, Dakai Xiao, Hong Wang, Alan Sandler, David H. Johnson, A. D. Colevas, Jennifer A. Low, Mace L. Rothenberg, Bo Lü - Clinical Cancer Research 2007 cited by 265

  21. A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

    Authors: Alan Sandler, Michael A. Gordon, Dinesh P. de Alwis, Isabelle Pouliquen, Lisa Green, Phil Marder, Ajai K. Chaudhary, Karen Fife, Linda A. Battiato, Christopher Sweeney, Christopher Jordan, Michael Burgess, Christopher A. Slapak - Clinical Cancer Research 2004 cited by 151

  22. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer

    Authors: Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, Diego Cortinovis, Thomas Karagiannis, Marcus Ballinger, Alan Sandler, Wei Yu, Pei He, Christina Matheny, Federico Felizzi, Achim Rittmeyer - Clinical Lung Cancer 2018 cited by 77

  23. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

    Authors: Roy S. Herbst, Diane Prager, Róbert Hermann, L. Fehrenbacher, Bruce E. Johnson, Alan Sandler, Mark G. Kris, Hai T. Tran, Pam Klein, Xin Li, David A. Ramies, David H. Johnson, Vincent A. Miller - Journal of Clinical Oncology 2005 cited by 1,497

  24. Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs

    Authors: Gregory A. Otterson, Miguel A. Villalona‐Calero, Sunil Sharma, Mark G. Kris, A. R. Imondi, Mirjam C. Gerber, Dorothy A. White, Mark J. Ratain, Joan H. Schiller, Alan Sandler, Michael Kraut, Sridhar Mani, John R. Murren - Clinical Cancer Research 2007 cited by 131